VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
First Selective TLR8 Agonist to Advance for Treatment of Allergy
“We are pleased to advance VTX-1463 into the clinic,” said Dr.
VTX-1463 is a small molecule TLR8 agonist that is being developed as a stand-alone agent for the treatment of allergic rhinitis. In preclinical animal studies, this compound has been shown experimentally to dramatically reduce allergic responses without requiring the concomitant administration of allergen. As such, it represents a potential prophylactic and/or therapeutic solution for allergic diseases, regardless of the antigen responsible for the allergic response. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic patients later this year.
“VTX-1463 is the first selective TLR8 compound to reach the clinic for allergy,” said
About VentiRx Pharmaceuticals
VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and inflammatory diseases. The Company’s initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in
SOURCE VentiRx Pharmaceuticals, Inc.